PEDIATRICS Vol. 121 No. 2 February 2008, pp. e387-e396 (doi:10.1542/peds.2007-0575)
SPECIAL ARTICLE |
Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group
a Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University, Nashville, Tennessee
b Division of Pediatric Hematology/Oncology, Department of Pediatrics
k Division of Pediatric Cardiology, Stanford University, Palo Alto, California
c Pediatric Hematology/Oncology, St Jude Children's Research Hospital, Memphis, Tennessee
d Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
e Division of Epidemiology, Community and Preventive Medicine, University of Rochester, Rochester, New York
f Division of Population Sciences, City of Hope Cancer Center, Duarte, California
g Children's Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles, Los Angeles, California
h Division of Women's Health and Gender Biology, Brigham and Women's Hospital, Boston, Massachusetts
i STAR Survivorship Program, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
j Division of Pediatric Cardiology, University of Minnesota, Minneapolis, Minnesota
Curative therapy for childhood cancer has improved significantly in the last 2 decades such that, at present,
80% of all children with cancer are likely to survive
5 years after diagnosis. Prevention, early diagnosis, and treatment of long-term sequelae of therapy have become increasingly more significant as survival rates continue to improve. Cardiovascular disease is a well-recognized cause of increased late morbidity and mortality among survivors of childhood cancer. The Children's Oncology Group Late Effects Committee and Nursing Discipline and Patient Advocacy Committee have recently developed guidelines for follow-up of long-term survivors of pediatric cancer. A multidisciplinary task force critically reviewed the existing literature to evaluate the evidence for the cardiovascular screening recommended by the Children's Oncology Group guidelines. In this review we outline the clinical manifestations of late cardiovascular toxicities, suggest modalities and frequency of monitoring, and address some of the controversial and unresolved issues regarding cardiovascular disease in childhood cancer survivors.
Key Words: cardiomyopathy anthracyclines radiation therapy cancer survivor
Abbreviations: COG—Children's Oncology Group CHF—congestive heart failure FS—fractional shortening EF—ejection fraction LVSD—left-ventricular systolic dysfunction HL—Hodgkin's lymphoma
Accepted Jun 15, 2007.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
W. Landier and S. Bhatia Cancer Survivorship: A Pediatric Perspective Oncologist, November 1, 2008; 13(11): 1181 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Mertens, Q. Liu, J. P. Neglia, K. Wasilewski, W. Leisenring, G. T. Armstrong, L. L. Robison, and Y. Yasui Cause-Specific Late Mortality Among 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor Study J Natl Cancer Inst, October 1, 2008; 100(19): 1368 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Armenian and S. Bhatia Cardiovascular disease after hematopoietic cell transplantation - lessons learned Haematologica, August 1, 2008; 93(8): 1132 - 1136. [Full Text] [PDF] |
||||
![]() |
K. A. Meeske and M. B. Nelson The Role of the Long-Term Follow-up Clinic in Discovering New Emerging Late Effects in Adult Survivors of Childhood Cancer Journal of Pediatric Oncology Nursing, July 1, 2008; 25(4): 213 - 219. [Abstract] [PDF] |
||||








